View Cart (0 items)
Amgen parathyroid drug for dialysis patients reaches endpoints in 2nd phase 3 study

Seventy-four percent of hemodialysis patients who received Amgen Inc.'s experimental drug AMG 416 as part of a second phase 3 study experienced a drop in their parathyroid hormone levels of more than 30%

Baxter reports supply constraints of peritoneal dialysis solutions

The company said they are instituting a process to temporarily limit the number of new peritoneal dialysis patient referrals across their entire base of customers

Dialysis Patient Citizens critical of Dialysis Facility Compare's five-star rating system

In a letter to CMS, Dialysis Patient Citizens expressed concern about the implementation of Dialysis Facility Compare's new five-star rating system

DaVita HealthCare Partners profit falls on HealthCare Partners poor earnings

DaVita HealthCare Partners Inc. reported that net income for the second quarter of 2014 fell 42% to $147.68 million, or $0.68 per share, compared to $254.38 million or $1.18 per share in the same quarter last year

WHAT'S NEW

Rss
Rss

Blogs

Preparing for the Wearable Artificial Kidney's first human clinical trial in the US

Preparing for the Wearable Artificial Kidney's first human clinical trial in the US

The Wearable Artificial Kidney, Invented by nephrologist Victor Gura, MD, FASN, from the David Geffen School of Medicine at UCLA, has been involved in laboratory and clinical testing since 2001 by medical clinicians, bio medical engineers, and other medical device researchers.

More
Socioeconomic impact on ESRD?

Socioeconomic impact on ESRD?

Sadly, the precise population that the medical safety net has promised to help, the socioeconomically disadvantaged, remain disproportionally at risk.

More

WHAT'S NEW

Rss
Rss

Blogs

Preparing for the Wearable Artificial Kidney's first human clinical trial in the US

Preparing for the Wearable Artificial Kidney's first human clinical trial in the US

The Wearable Artificial Kidney, Invented by nephrologist Victor Gura, MD, FASN, from the David Geffen School of Medicine at UCLA, has been involved in laboratory and clinical testing since 2001 by medical clinicians, bio medical engineers, and other medical device researchers.

More
Socioeconomic impact on ESRD?

Socioeconomic impact on ESRD?

Sadly, the precise population that the medical safety net has promised to help, the socioeconomically disadvantaged, remain disproportionally at risk.

More